The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Tandem Meetings 2023 | Phase I study of pevonedistat and ibrutinib in R/R B-NHL
Swetha Kambhampati, MD, City of Hope, Duarte, CA, shares the results of a Phase I study of pevonedistat in combination with ibrutinib in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (NCT03479268). The study reported that the combination was overall well-tolerated, and noted a promising efficacy in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
